Latest From Biotech Now

Think Organic Farming is Better for the Environment? Think Again.

brookes_pf

The eighth annual Global Impacts Study released this week by PG Economics quantifies the environmental benefits gained from the use of biotech crops. “We’ve seen a significant reduction in the use of chemical insecticides with biotech crops,” said Dr. Cathleen Enright, BIO’s executive vice president for food and agriculture. “Since 1996 and the advent of agricultural biotechnology, farmers growing these crops have switched to more benign herbicides to help control weeds.” Enright adds, “The shift Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Protect Yourself from a Hack Attack

Protect Yourself from a Hack Attack

Gone are the days when biotech’s biggest activist threats came from lab break-ins and physical attacks. Today almost anyone wishing to damage companies can steal, disrupt or harm employees 24-hours a day and from anywhere in the world. Hackers are anything BUT anonymous Last year the notorious group Anonymous took credit for hacking Monsanto Co. due to the company’s alleged “crimes against humanity.” It was the third hack Anonymous aimed against the the company, and Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The Ethics of the Market Access Debate

Rogerio Vivaldi

At the core of the market access conversation lies the question of value. How much do we value two years added to the end of an 80-year-old’s life? How do we put a dollar amount on a medicine that prevents a rare disease patient, who may only live to age 20 regardless of receiving treatment, from losing her ability to walk? How can we define metrics to measure the cost of a child with a Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Managed Entry Trumps Risk Sharing

Since 2000, pharmaceu-tical and biotech companies have engaged in agreements with government and private payers across the world to gain market access for their innovative drugs despite struggles to qualify for formal reimbursement criteria, such as the cost effectiveness threshold from NICE in the UK. These agreements, usually referred to as “risk sharing” agreements, have had a wide variety of structures but usually do not involve any sharing of risk, as the name misleadingly suggests. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Ernst & Young’s Beyond Borders: Matters of Evidence

Super Session

Hundreds of attendees turned out to glean insights from findings outlined in Ernst & Young LLP’s (EY) 27th annual report on the biotechnology industry – Beyond borders: matters of evidence – officially launched at Tuesday morning’s Super Session at the 2013 BIO International Convention. The report was presented by Glen Giovannetti and Gautam Jaggi of EY’s Global Life Sciences Center, and the Super Session featured a panel of industry leaders, including: Brian Edelman, VP, Corporate Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,